Veterinarians seeking consistent, natural options to support equine tissue health are increasingly exploring amniotic tissue-based products. RenoVō® is a ready-to-use, acellular amniotic tissue allograft developed specifically for equine use. One of the naturally occurring proteins present in this tissue is TIMP-2 (Tissue Inhibitor of Metalloproteinase-2). Understanding its biological role within the extracellular matrix helps contextualize why it is retained in RenoVō®’s formulation.
What is TIMP-2?
TIMP-2 is part of a family of proteins that regulate the activity of matrix metalloproteinases (MMPs), which are enzymes involved in the breakdown of extracellular matrix components. This activity plays a role in normal physiological tissue remodeling. TIMP-2 naturally inhibits specific MMPs, contributing to regulation of the extracellular matrix environment.
Its presence in amniotic tissue reflects the complexity of the biologically active environment found in fetal-derived tissues.
TIMP-2 in RenoVō®
RenoVō® is derived from equine amniotic fluid and membrane. It is an acellular allograft, processed aseptically and sterility tested. The manufacturing process is designed to retain components intrinsic to amniotic tissue, including:
- TIMP-2 (Tissue Inhibitor of Metalloproteinase-2)
- IL-1ra (Interleukin-1 Receptor Antagonist)
- A2M (Alpha-2-Macroglobulin)
Because RenoVō® contains no living cells, such as red or white blood cells, it is not dependent on cellular viability or activity. This contributes to consistency in composition and avoids the variability that may occur with autologous blood-derived products.
The Biological Context of TIMP-2
In biological systems, TIMP-2 plays a role in modulating enzymatic activity involved in extracellular matrix turnover. As a naturally occurring protein found in amniotic tissue, its presence supports the intended use of RenoVō®: to supplement and protect tissues.
RenoVō® is not intended to diagnose, treat, or prevent any disease or condition. The presence of TIMP-2, along with other proteins such as IL-1ra and A2M, reflects the native composition of amniotic tissue. These elements are retained through the product’s aseptic manufacturing process.
Considerations for Clinical Use
RenoVō® is supplied in a ready-to-use format and does not require on-site preparation. This may be a practical consideration for veterinary professionals working in clinic or field settings. Key product characteristics include:
- Aseptic processing and sterility testing
- Consistent, acellular formulation
- No on-site preparation required
- Intended to supplement and protect tissues
Veterinarians may use RenoVō® at their discretion in accordance with the product’s labeled purpose. As with any tissue-based allograft, product selection and use should be based on individual clinical judgment.
Veterinary professionals who prioritize consistency, standardization, and biologically sourced materials may find value in incorporating equine amniotic tissue products such as RenoVō® into their practice.
RenoVō® is labeled and marketed for equine use to supplement and protect tissues. It is not intended for the diagnosis, cure, mitigation, treatment, or prevention of disease. Any use is at the discretion of a licensed veterinarian.
If you would like to learn more or connect with a colleague who has experience using RenoVō® in practice, we welcome you to fill out a contact form here. A member of our team can follow up with additional information or facilitate a connection upon request.
